Nevertheless, further “in vivo” clinical study should be necessary to clarify the role of anticholinergic drugs in the control of mucus and inflammatory mediator secretion from bronchial epithelial cells during IL-17A mediated airway inflammation. Here, IL17A is linked to inflammatory response.